KPF
CEROW

K2 Principal Fund’s CERo Therapeutics Warrants CEROW Stock Holding History

K2 Principal Fund’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-75,000
Closed -$6K – 326
2022
Q3 		$6K Hold
75,000
– – ﹤0.01% 270
2022
Q2 		$8K Hold
75,000
– – ﹤0.01% 347
2022
Q1 		$14K Hold
75,000
– – ﹤0.01% 294
2021
Q4 		$32K Buy
+75,000
New +$34.6K ﹤0.01% 360

Other funds holding CEROW

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

K2 Principal Fund's CEROW Position: Q4 2022 in Review

K2 Principal Fund sold out of CERo Therapeutics Warrants (CEROW) in Q4 2022, closing a stake of 75,000 shares — an estimated $6K sold.

K2 Principal Fund first reported a position in CEROW in Q4 2021 and held it in 4 quarters. The position peaked at $32K in Q4 2021. 49 funds tracked by Wall St. Rank hold CEROW as of Q4 2022.

  • K2 Principal Fund reported no remaining CERo Therapeutics Warrants position as of Q4 2022 after selling out during the quarter.
  • K2 Principal Fund sold 75,000 CERo Therapeutics Warrants shares in Q4 2022, an estimated $6K.
  • K2 Principal Fund first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 4 quarters.
  • K2 Principal Fund's CERo Therapeutics Warrants position peaked at $32K in Q4 2021.
  • 49 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2022.

Based on K2 Principal Fund's 13F filing for Q4 2022, filed 10 Feb 2023.